This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Zedira Gmbh. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Kai Oertel: Pioneering Research in Transglutaminase Inhibitors
Introduction
Kai Oertel is an innovative inventor based in Frankfurt-am-Main, Germany. With a keen focus on advancements in medical research, she has made significant contributions to the field through her work at Zedira GmbH. Her groundbreaking research aims to address critical health issues, particularly coeliac disease, through the development of novel pharmaceutical compounds.
Latest Patents
Oertel holds one notable patent titled "Michael systems as transglutaminase inhibitors." This patent outlines the potential of peptide derivatives and peptidomimetics as effective inhibitors for transglutaminases. It details methods for their preparation, pharmaceutical compositions containing these compounds, and their specific uses in treating coeliac disease and other transglutaminase-dependent diseases.
Career Highlights
During her tenure at Zedira GmbH, Kai Oertel has been at the forefront of research aimed at creating innovative solutions in the pharmaceutical industry. Her work has not only contributed to the understanding of transglutaminases but also paved the way for new treatments that could potentially enhance the quality of life for patients suffering from related ailments.
Collaborations
Throughout her career, Oertel has engaged in various collaborations with research institutions and other companies within the pharmaceutical sector. These partnerships have facilitated the exchange of knowledge and resources, enabling her to further her research and amplify the impact of her inventions.
Conclusion
Kai Oertel's work as an inventor is a testament to the potential of innovative research in addressing complex medical challenges. Her dedication to developing effective transglutaminase inhibitors demonstrates her commitment to improving health outcomes for individuals affected by conditions like coeliac disease. As she continues her endeavors at Zedira GmbH, the scientific community eagerly anticipates the future advancements that may arise from her research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile